小范围局部肿瘤(T1-T2/N0)患者的新发转移性乳腺癌:特征与预后
该回顾性比较研究基于ESME-MBC队列,纳入2008–2016年法国治疗的dnMBC患者,比较非指南推荐分期(NGS)与指南推荐分期(GS)诊断的dnMBC患者特征与预后。
要点
- T1-T2/N0患者中经非指南推荐分期诊断的dnMBC占dnMBC的6%、总人群的1%。
- NGS组患者更年轻(57 vs 59岁,p=0.02)且转移部位更少。
核心结论
- 小范围局部肿瘤(T1-T2/N0)患者中经非指南推荐分期诊断的dnMBC更年轻、转移部位更少且预后更好。
研究设计与样本
- 回顾性比较研究,基于ESME-MBC队列,纳入2008–2016年法国治疗的dnMBC患者。
- 研究期间ESME队列共纳入22,463例MBC患者,其中dnMBC患者6,698例。
- 比较非指南推荐分期(NGS)诊断的dnMBC与指南推荐分期(GS)诊断的dnMBC两组人群。
主要发现
- NGS组247例,占dnMBC的6%、总人群的1%。
- NGS组患者显著更年轻(57 vs 59岁,p=0.02),诊断时转移部位更少。
- 两组其他特征无显著差异。
- NGS组OS和PFS均优于GS组,单因素和多因素分析确认生存影响(HR 1.83 [1.31-2.57],p<0.01)。
临床怎么用
- 对于小范围局部肿瘤(T1-T2/N0)患者,即使无指南分期指征,也应警惕dnMBC可能,尤其年轻患者。
- NGS诊断的dnMBC患者预后较好,可能适合更积极的局部或系统治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The estimated rate of de novo metastatic breast cancer (dnMBC) at the time of diagnosis is between 5 to 12%. International guidelines recommend metastatic work-up (MWU) only in women with advanced breast cancer. The purpose of this study was to describe the characteristics and prognosis of patients with dnMBC diagnosed without an initial indication for MWU. METHODS: We conducted a retrospective, comparative study in dnMBC patients selected from the ESME-MBC cohort. Patients were treated in France between 2008 and 2016. We compared two populations: patients in whom dnMBC was diagnosed by staging although not indicated by guidelines (non-guideline staging [NGS]) and those in whom dnMBC was diagnosed by guideline staging (GS). RESULTS: During the study period, 22,463 patients with MBC were included in the ESME cohort. Among them, 6698 were dnMBC patients. In 247 of these patients (6% of dnMBC and 1% of the overall population), dnMBC was diagnosed by non-guideline staging. Women in this group were significantly younger (57 vs. 59 years, p = 0.02) and had fewer metastatic sites at diagnosis than dnMBC-GS patients. The two groups were not significantly different in terms of the other characteristics. Overall survival (OS) and progression-free survival (PFS) were better in the dnMBC-NGS group than in the dnMBC-GS group. The impact on survival was confirmed by univariate and multivariate analysis (HR 1.83 [1.31-2.57], p < 0.01). CONCLUSION: This study provides the first description of a very specific population. These patients with dnMBC-NGS were younger and more likely to have oligometastatic disease with a better prognosis.
引用
- Gaillard T, Carton M, Mailliez A, et al. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis. Eur J Cancer. 2021. PMID: 34689042. doi:10.1016/j.ejca.2021.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。